METHOD

Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.

Description: METHOD Tne present invention relates to a method of vaccination wnicn involves using photodynamic treatment (PDT) to introduce vaccine components into cells to achieve antigen presentation, and to vaccine compositions useful in such a method. The majority of molecules do not readily penetrate cell membranes. Methods for introducing molecules into the cytosol of living cells are useful tools for manipulating and studying biological processes. Among the most commonly used metnods today are micromjectioπ, red blood cell ghost -mediated fusion and liposome fusion, osmotic lysis of pinosomes, scrape loading, electroporation, calcium phosphate and virus-mediated transfection. These techniques are useful for investigating cells m culture, although m many cases they may be impractical, time consuming, inefficient or they may induce significant ceil death. Thus such techniques are not optimal for use m biological or medical research, or m therapies, where it is r. uired that: cells should remain viable and/or functional. It is well known that pcrpnyrins and many other photosensitizing compounds may mαuce cytotoxic effects on cells and tissues. Tnese effects are based upon the fact that upon exposure to ligr.t tne photosensitizing compound may £>ecome toxic cr may release toxic substances sucn as singlet 0 cr otner oxidising radicals whicn are damaging to cellular material or biomolecules , including tne memr>ranes cf cells and cell structures, and sucn cellular cr membrane αamage may eventually Kill the cells. Tnese effects nave oeen utilised in. the treatment of various abnorma ies or disorders, including especially neoplast diseases. The treatment is named photodynamic therapy (PDT) and involves the administration of pnotosens t tmg (photochemotherapeutic) agents to the affected area of the body, followed by exposure to photoactivating light in order to activate the photosensitizing agents and convert them into cytotoxic form, whereby the affected cells are killed or their proliferative potential diminished. Photosensitizing agents are known which will localise preferentially or selectively to the desired target site e.g. to a tumour or other lesion. A range of photosensitizing agents are known, including notably the psoralens, the porphyrins, the chlorins and the phthalocyanins . Such drugs become toxic when exposed to light . Photosensitizing drugs may exert their effects by a variety of mechanisms, directly or indirectly. Thus for example, certain photosensitisers become directly toxic when activated by light, whereas others act to generate toxic species, e.g. oxidising agents such as singlet oxygen or other oxygen-derived free radicals, which are extremely destructive to cellular material and biomolecules such as lipids, proteins and nucleic acids. Porphyπn photosensitisers act indirectly by generation of toxic oxygen species, and are regarded as particularly favourable candidates for PDT. Porphyrins are naturally occurring precursors m the synthesis of heme . In particular, heme is produced when iron ( Fe N is incorporated m protoporphyrm IX (Pp) by the action of the enzyme ferrochelatase . Pp is an extremely potent photosensitize!", whereas heme has no photosensitizing effect. A variety of porphyrm-based cr porphyπn- related photosensitisers are known in tne art and described in the literature. The cytotoxic effect is mediated mainly through the formation of singlet oxygen. This reactive intermediate has a very short lifetime m cells (<0.04 μs) . Tnus, the primary cytotoxic effect of PDT is executed during light exposure and very close to the sites of formation of 'O . 0 reacts with and oxidizes proteins (histidme, tryptophan, methionme, cysteme, tyrosme) , DNA (guanme) , unsaturated fatty acids and cholesterol. One of the advantages of PDT is that tissues unexposed to light may be left unaffected le. that a selective PDT effect may be obtained. There is extensive documentation regarding use of PDT to destroy unwanted cell populations, for example neoplastic cells. The patent literature describes a number of photodynamic compounds, alone or conjugated with targeting agents, e.g. immunoglobulins directed to neoplastic cell receptor determinants, making the complex more cell specific. Certain photochemical compounds, such as hematoporphyrin derivatives, have furthermore an inherent ability to localise m malignant cells. Such methods and compounds, are described m the Norwegian patent NO 173319, m Norwegian patent applications Nos . 90 0731, 176 645, 176 947, 180 742, 176 786, 301 981, 30 0499 and 89 1491. In 093/14142 a drug delivery system is described which comprises an anti- cancer agent and a photoactivatable agent de. a photosensitizer) attacned to copolymeric carriers. Upon administration this complex enters the cell interior by pmocytosis or phagocytosis and locates inside the endosomes and lysosomes . In the lysosomes, the bond between the anti- neoplastic agent and the polymer is hydrolysed and tne former can diffuse passively through the lysosome membrane into the cytosol. The utility of this method is thus limited to small molecular compounds wnich are able to diffuse across the lysosome membranes. Afte_ allowing a time lag for diffusion, a light source of appropriate wavelength and energy is applied to activate tne photo-activatable compound. The comoinea effect of the an -cancer agent and pnotoact lvatable agent destroy the cell . Such PDT methods as described above are thus directed to the destiuction of cell structures leading to cell death. WO 96/07432, on the other hand, is concerned with methods which use the photodynamic effect as a mechanism for introducing otherwise membrane-impermeable molecules into the cytosol of a cell m a manner which does not result m widespread cell destruction or cell death. In this method, the molecule is co-mternalised (more particularly "endocytosed" ) into an mtracellular vesicle m the cell (e.g. a lysosome or endosome) together with a photosensitizing agent. The cell is then exposed to photoactivatmg light which "activates" the photosensitizer, which m turn causes the vesicle membrane to disrupt or rupture, releasing the vesicle contents, including the molecule, into the cell interior le . the cytosol. It was found that m such a method the functionality or the viability of the majority of the cells was not deleteπously affected. Thus, the utility of such a method, termed "photochemical intemalisation" was proposed for transporting a variety of different molecules, including therapeutic agents, into the cytosol le . into the interior of a cell. We have now found that such a method can advantageously be used, not only to transfer molecules m the interior of a cell, but also to present or express them on a cell surface. Thus, following transport and release of a molecule into the cell cytosol, it may be transported to tne surface of the cell where it may be presented on tne outside of the cell le. on the cell surface. Such a method has particular utility m the field of vaccination, wnere vaccine components le . antigens cr immunogens, nay be introduced to a cell for presentation on the surface of that cell, m order to induce, facilitate or augment an immune response . At its most general, the present invention thus provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell, preferably an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical intemalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell . As used herein "expressing" or "presenting" refers to the presence of the molecule or a part thereof on the surface of said cell such that at least a portion of that molecule is exposed and accessible to the environment surrounding that cell. Expression on the "surface" may be achieved m which the molecule to be expressed is m contact with the cell membrane and/or components which may be present or caused to be present m that membrane . Such antigenic presentation may advantageously result in the stimulation of an immune response, preferably an immune response which confers protection against subsequent challenge by an entity comprising or containing said antigen molecule or part thereof, and consequently the invention finds particular utility as a method of vaccination. More particularly, this aspect of the invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell, said metnod comprising: contacting said cell with said antigenic molecule and with a photosensitizing agent, wherein said molecule and said agent are each taken up into an mtracellular membrane-restricted compartment of said cell; and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, such that the membrane of said mtracellular compartment is disrupted, releasing said molecule into the cytosol of the cell, without killing tne cell, wherein, said released antigenic molecule, or a part tnereof, is subsequently presented on the surface As used herein, a "disrupted" compartment refers to destruction of the integrity of the membrane of that compartment either permanently or temporarily, sufficient to allow release of the antigenic molecule contained within it . Alternatively viewed, this aspect of the invention also provides a composition for use m expressing an antigenic molecule or a part thereof on the surface of a cell, preferably to simulate an immune response, said composition comprising an antigenic molecule and a photosensitizing agent. Preferably said composition is pharmaceutically acceptable and contains also a pharmaceutically acceptable excipient or diluent. In a further aspect, the invention also provides the use of an antigenic molecule and a photosensitizing agent m the preparation of a medicament for use m expressing said antigenic molecule or a part thereof on the surface of a cell to stimulate an immune response. A still further aspect of the invention provides a product comprising an antigenic molecule and a photosensitizing agent as a combined preparation for simultaneous, separate or sequential use m expressing said antigenic molecule or a part thereof on the surface of a cell, preferably to stimulate an immune response. A yet further aspect of the invention provides a kit for use m expressing an antigenic molecule or a part thereof on the surface of a cell, said kit comprising a first container containing said antigenic molecule; and a second container containing a photosensitizing agent . In the invention, tne antigenic molecule may be any molecule wherein that molecule or a part thereof is capable of stimulating an immune response, when presented to the immune system m an appropriate manner. Advantageously, therefore the antigenic molecule will be a vaccine antigen or vaccine component, such as a polypeptide containing entity. Many such antigens or antigenic vaccine components are known m the art and include all manner of bacterial or viral antigens or indeed antigens or antigenic components of any pathogenic species including protozoa or higher organisms. Whilst traditionally the antigenic components of vaccines have comprised whole organisms (whether live, dead or attenuated) ie . whole cell vaccines, m addition sub-unit vaccines, ie . vaccines based on particular antigenic components of organisms e.g. proteins or peptides, or even carbohydrates, have been widely investigated and reported in the literature. Any such " sub-unit " -based vaccine component may be used as the antigenic molecule of the present invention. However, the invention finds particular utility in the field of peptide vaccines. Thus, a preferred antigenic molecule according to the invention is a peptide (which is defined herein to include peptides of both shorter and longer lengths ie . peptides, oligopeptides or polypeptides , and also protein molecules or fragments thereof e.g. peptides of 5-500 e.g. 10 to 250 such as 15 to 75, or 8 to 25 ammo acids) . Parts of antigenic molecules which are presented or expressed preferably comprise parts which are generated by antigen-processmg machinery within the cell. Parts may however be generated by other means which may be achieved through appropriate antigen design le.g. pH sensitive bands) or through other cell processing means. Conveniently such parts are of sufficient size to generate an immune response, e.g. in the case cf peptides greater than 5, e.g. greater than 10 or 20 ammo acids in size. A vast number of peptide vaccine candidates have been proposed m the literature, for example the treatment of viral diseases and infections such as AIDS/ HIV infection or influenza, canine parvovirus, bovine leukaemia virus, nepatitis, etc. (see e.g. Phanuphak et al . , Asian Pac . J. Allergy. Immunol. 1997, 15(1), 41-8; Naruse, Hokkaido Igaku Zasshi 1994, 69(4), 811-20; Casal et al . , J. Virol., 1995, 69(11), 7274-7; Belyakov et al . , Proc. Natl . Acad. Sci . USA, 1998, 95(4), 1709-14; Naruse et al . , Proc. Natl. Sci . USA, 1994 91(20), 9588- 92; Kabeya et al . , Vaccine 1996, 14(12), 1118-22; Itoh et al . , Proc. Natl. Acad. Sci. USA, 1986, 83(23) 9174-8. Similarly bacterial peptides may be used, as indeed may peptide antigens derived from other organisms or species. In addition to antigens derived from pathogenic organisms, peptides have also been proposed for use as vaccines against cancer or other diseases such as multiple sclerosis. For example, mutant oncogene peptides hold great promise as cancer vaccines acting an antigens m the simulation of cytotoxic T- lymphocytes . (Schirrmacher, Journal of Cancer Research and Clinical Oncology 1995, 121, 443-451; Curtis Cancer Chemotherapy and Biological Response Modifiers, 1997, 17, 316-327) . A synthetic peptide vaccine has also been evaluated for the treatment of metastatic melanoma (Rosenberg et al . , Nat. Med. 1998, 4(3), 321-7). A T-cell receptor peptide vaccine for the treatment of multiple sclerosis is described m Wilson et al., J. Neuroimmunol . 199 " , 76(1- 2), 15-28. Any such peptide vaccine component may be used as the antigenic molecule of the invention, as indeed may any of the peptides described or proposed as peptide vaccines m the literature The peptide may thus be synthetic or isolated or otherwise derived from an orgamsrr. The cell which is subjected to tne methods, ases etc. of the invention may be any cell which is capable of expressing, or presenting on its surface a molecule which is administered or transported into its cytosol Since the primary utility of the invention resides antigen-presentation or vaccination, the cell is convenient! / an immune effector cell ie. a cell involved the immune response. However, other cells may also present antigen to the immune system and these also fall within the scope of the invention. The cells according to the present invention are thus advantageously antigen-present g cells. The antigen-presenting cell may be involved in any aspect or "arm" of the immune response, including both humoral and cell -mediated immunity, for example the stimulation of antibody production, or the stimulation of cytotoxic or killer cells, which may recognise and destroy (or otherwise eliminate) cells expressing "foreign" antigens on their surface. The term "stimulating an immune response" thus includes all types of immune responses and mechanisms for stimulating them. The stimulation of cytotoxic cells or antibody- producing cells, requires antigens to be presented to the cell to be stimulated in a particular manner by the antigen-presentmg cells, for example MHC Class I presentation (e.g. activation of CD8 " cytotoxic T-cells requires MHC-1 antigen presentation) . Antigen-present g cells are known m the art and described m the literature and include for example, lymphocytes (both T and B cells) , dendritic cells, macrophages etc. Others include for example cancer cells e.g. melanoma cells. For antigen presentation by an antigen-present g cell to a cytotoxic T-cell (CTL) the antigenic molecule needs to enter the cytosol of the antigen-presentmg cell (Germain, Cell, 1994, 76, 287-299). The present invention provides an efficient means of delivery of the antigenic molecule into the cytosol . Once released m the cell cytosol by the photochemical inte alisation process, the antigenic molecule may be processed by the antigen-processmg machinery of the cell and presented on the cell surface in an appropriate manner e.g. toy Class I MHC. This processing may involve degradation of tne antigen, e.g. degradation of a protein or polypeptide antigen into peptides, which peptides are then complexed with molecules of the MHC for presentation. Thus, the antigenic molecule expressed or presented on the surface of the cell according to the present invention may be a part or fragment of the antigenic molecule which is internalised (endocytosed) . Antigens may be taken up by antigen-presentmg cells by endocytosis and degraded in the endocytic vesicles to peptides. These peptides may bind to MHC class II molecules in the endosomes and be transported to the cell surface where the peptide-MHC class II complex may be recognised by CD4+ T helper cells and induce an immune response. Alternatively, proteins in the cytosol may be degraded, e.g. by proteasomes and transported into endoplasmic reticulum by means of TAP (transporter associated with antigen presentation) where the peptides may bind to MHC class I molecules and be transported to the cell surface as illustrated the figure 1 (Yewdell and Bennink, 1992, Adv. Immunol. 52: 1-123) . If the peptide is of foreign antigen origin, the peptide-MHC class I complex will be recognised by CD8+ cytotoxic T-cells (CTLs) . The CTLs will bind to the peptide-MHC (H A) class I complex and thereoy de activated, start to proliferate and form a clone of CTLs. The target cell and other target cells with the same peptide-MHC class I complex on the cells surface may be killed by the CTL clone. Immunity against the foreign antigen may be established if a sufficient amount of the antigen can be introduced into the cytosol (Yewdell and Bennink, 1992, supra; Roc.;, 1996, Immunology Today 17: 131-137) . This is the basis for development of inter al ia cancer vaccines. One of the largest practical problems is to introduce sufficient amounts of antigens (or parts of the antigen) into the cytosol . This may be solved according to the present invention by PCI. This principle is illustrated m Fig. 1, which shows how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen-presentmg cells. P is endocytosed and released into cytosol by PCI . The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the complex can be recognised by CTLs. As will be described more detail the Examples below, it has been demonstrated that photochemical intemalisation may be used efficiently according to the present invention for cytosolic delivery of cancer- specific peptides. The antigenic molecule and/or photosensitivity agent may be targeted to specific cells or tissues by employing targeting agents e.g. target -specific delivery or carrier systems or carrier molecules. Thus for example the antigenic molecule and/or photosensitis g agent may be delivered to the cell using a vector or carrier system e.g. reconstituted LDL-particles . The carrier molecule may be bound or conjugated to the antigenic molecule, to the photosensitismg agent or both, and the same or different carrier molecules may be used. The antigenic molecule and/or photosensitismg agent may also be conjugated to a site- targeting liganα, such as a ligand which is specific for particular cell- types or particular cell structures e.g. an antibody recognising a surface antigen expressed on certain cell types e.g. a tumour- specific antigen Such mechanisms may act to increase uptake of the pnotosensitiser and/ci antigen molecule through receptor-mediated endocytosis Such targeting molecules carriers or vectors may also De used to direct tne antigenic molecule and/or photosensitismg agent to the mtracellular compartment The mtracellular membrane-restricted compartment may be any sucn compartment which is present a cell Preferably the comoartment will be a membrane vesicle, especially an endosome or a lysosome However, the mtracellular compartment may also include the Golgi apparatus or the endoplasmic reticulum. All that is required is that the antigenic molecule and the photosensitismg agent locate to the same mtracellular compartment (s) . The photochemical intemalisation process is described m more detail m WO 96/07432 (the contents of which are incorporated herein by reference) . Methods of PDT are also now widely described m the literature. The photosensitizing agent to be used according to the present invention may be any such agent which localises to mtracellular compartments, particularly endosomes or lysosomes . A range of such photosensitismg agents are known in the art and are described m the literature, including m WO96/07432. Mention may be made this respect of di- and tetrasulfonated aluminium phthalocyan e , sulfonated tetraphenylporphmes (TPPS r ), rule blue, chlorm e derivatives, uroporphyr I, phylloerythrm, hematoporphyrm and methylene blue which have been shown to locate m endosomes and lysosomes of cells m culture This is most cases due to endocytic activity . Classes of suitable photosensitismg agent which may be mentioned thus include porpryrms, phthalocyanmes , purpur s, chlorms, benzoporphynns naphthalocyanmes , catio ic dyes, tetracyclmes and lysomotropic weak bases or derivatives thereof (Berg et al . , Photochemistry and Photobιolog_> , 1997, 65, 403- 409) . Preferred photosensitismg agents include TPPS (Zabner et al . , J. Biol Cherr 199Ξ, 270, 18997-19007) TPPS and AlPcS . The photochemical inte alisation according to the present invention may be carried out using PDT methods nich are known and standard the art and appropriate modifications of such techniques which are effective in this method. Thus, the antigenic molecule and photosensitising agent may be delivered to the cell by application or administration according to methods and means known in the art of PDT. The methods of the present invention may be used in vi tro or in vivo, either by in si tu treatment or by ex vi vo treatment, followed by administration of the treated cells. Thus, a further aspect of the invention provides an antigen-presentmg cell expressing an antigenic molecule, or a part thereof, on its surface, which cell is obtainable (or obtained) by a method as hereinbefore defined. Other aspects of the invention provide a population or culture of such cells, especially a viable and functionally intact population or culture of such cells, and also the use of such a cell (or population or culture of cells) in therapy, particularly for stimulating an immune response, and especially for stimulating CTLs. Also provided is the use of such a cell (or population or culture of cells) for the preparation of a medicament (e.g. a vaccine composition' for stimulating an immune response, and especially for stimulating CTLs. In vivo, any mode of administration common or standard m the art may be used, e.g. injection, infusion, topical administration, both to internal and external body surfaces etc. For in vi vo use, the invention can be used relation to any tissue which contains the target cells, including body fluid locations, as well as solid tissues. All tissues can be treated as long as the photosensitiser is taken up by the target cells, and the light can be properly delivered . Thus, the compositions of the invention may be formulated m any convenient manner according to techniques and procedures known m tne pharmaceutical art, e.g. using one or more pharmaceutically acceptable carrier or excipients. The nature of the composition and carriers or excipient materials, dosages etc. may be selected m routine manner according to choice and the desired route of administration, purpose of vaccination etc. Dosages may likewise be determined routine manner and may depend upon the nature of the antigenic molecule, purpose of vaccination, age of patient, mode of administration etc., m connection with the photosensitismg agent the potency/ability to disrupt membranes on irradiation, should also be taken into account . The light irradiation step to activate the photosensitismg agent may likewise take place according to techniques and procedures well known m the art . For example, the wavelength and intensity of the light may be selected according to the photosensitismg agent used. Suitable light sources are well known m the art. As mentioned earlier, and as described WO96/07432, it has been found that photochemical intemalisation m this manner does not deleteriously affect the viability and functionality of the cells. In particular, it has been found that when a population or plurality of cells is treated according to the present invention, a majority of the cells are not killed, and survive the treatment, substantially functionally intact As used herein, the term "without killing the cell" is intended to define such a situation. In other words m a population or plurality of cells, substantially all of the cells, or a significant majority (e.g. at least 75%, more preferably at least 80, 85, 90 or 95% of the cells) are not killed Cleaily when dealing with the light irradiation of a population or a plurality of cells it is possible that certain groups of cells or certain areas of tissue may receive more light oi some other way be suojected to a larger PCI effect that other groups of cells or areas of tissue. Thus, the percentage values given for cell survival are not necessarily uniform across the entire irradiated population and refer to the percent of viable cells which remain in the irradiated population, the requirement being only that a sufficient portion of the irradiated cells survive. In addition, cell death induced by irradiation may take some time, e.g. a number of hours to occur. In this case it can be seen that cells which eventually die might also be able to express an antigenic molecule on their surface in accordance with the methods of the present invention and may thus be involved m the methods, uses etc. of the present invention. Thus the % cell death refers to the percent of cells which remain viable within a few hours of irradiation (e.g. up to 4 hours after irradiation) but preferably refers to the % viable cells 4 or more hours after irradiation. The methods of the invention may be modified such that the fraction or proportion of the surviving cells is regulated by selecting the light dose m relation to the concentration of the photosensitivity agent. Again, such techniques are known the art . The present invention provides an efficient means for delivery of a large variety of antigenic molecules. The invention has a number of features rendering it particularly suitable as a vaccine delivery tool: 1) it has no restrictions on the size of the molecule to be delivered as long as the molecule can be endocytosed by the target cell; 2) it is not dependent on cell proliferation; 3) it is site specific m that only areas exposed to light are affected; 4) it is not oncogenic. In addition, photochemical intemalisation may potentially be combined with other principles for generating site or tissue specific drug action, such as targeting by the use of specific ligands for cell surface structures, employing regulatory gene elements that confer tissue specificity or the use of disease- specific drugs, opening a possibility of obtaining substantially synergistic effects the specificity of drugs for target cells. The invention will now be described m more detail m the following non- limiting Examples with reference to the following drawings m which: Figure 1 shows a schematic representation of how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen presenting cells. P is endocytosed and released into cytosol by PCI The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the complex can be recognised by CTLs. Figure 2 shows photochemically induced relocalisation of a peptide. BL2-G-E6 cells were incubated with a fluorescem-labelled p21 ras -derιved 5- 21, Val 1 peptide and AlPcS The cells were examined for fluorescem-peptide and AlPcS localisation by fluorescence microscopy before (top panels) and 30 minutes after (bottom panels) a 4 -mm exposure to red light Bar 20 μm Figure 3 shows the cytotoxicity of a CD8 T lymphocyte clone against FM3 melanoma cells after PCI of a MART-1 peptide Figure 4 shows the ability of PCI to deliver HRP into the cytosol NHIK 3025 cells were treated with 3.2 μg/ml TPPS and 1 mg/ml HRP for 18 hours The medium was then replaced with drug- free medium before exposure to the indicated light doses HRP activity was measured m intact cells (O) and m cytosol (•) separated trom cytosol-free cell corpses (T) by electropermeabii sation and a density centπfugation technique Figure 5 shows photochemically induced expression of GFP. a expression of GFP m THX cells treated with pEGFP-Nl -pLys comple> m tne absence of AlPcS ana light or m the presence of AlPcS followed by exposure to light as indicated on the figure. The cells were analysed by flow cytometry, reckoning the cells on the right side of the drawn line as positive for GFP expression, b. expression of GFP in THX cells treated for 18 hours with a photosensitiser (20 μg/ml AlPcS 2a or 0.25 μg/ml 3-THPP) followed by a 6 hour transfection with pEGF-Nl-pLys complex and exposure to light inactivating 50% of the cells. GFP expression was analysed by flow cytometry as described a. EXAMPLES Materials and Methods Irradiation Two different light sources were used for treatment of the cells, both consisting of a bank of 4 fluorescent tubes. Cells treated with TPPS 4 , TPPS 2a , and 3-THPP (Porphyrin Products, Logan, UT) were exposed to blue light (model 3026; Appl. Photophysics, London, UK) with a light intensity reaching the cells of 1.5 mW/cm 2 while cells treated with AlPcS 2a (Porphyrin Products, Logan, UT) were exposed to red light (Philips TL 20W/09) filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35 mW/cirr. Fluorescence microscopy The cells were analysed by fluorescence microscopy as described in Berg. K. , et al . , Biochem. Biophys. Acta., 1370: 317-324, 1998. For analysis of fluorescem- labelled molecules the microscope was equipped with a 450-490 nm excitation filter, a 510 nm dichroic beam splitter and a 510-540 nm band pass emission filter. Preparation of Plasmid-pLys Complexes and Treatment of cells Plasmid-pLys complexes (charge ratio, 1.7) were prepared by gently mixing 5 μg plasmid (pEGFP-Nl; Clontech Laboratories, Inc., Palo Alto, C~x 75 μl c f KΞS with 5.3 μg pLys (MW 20700; Sigma, St. Louis, MO) in 75 μl of HBS . The solutions were incubated for 30 mm at room temperature, diluted with culture medium and added to the cells . THX cells were incubated with 20 μg/ml AlPcS 2a for 18 hours at 37°C, washed and incubated m sensitizer-free medium for 3 hours before incubation with plasmid-pLys complexes for 2 hours. The pEGFP-Nl/pLys treated THX cells were washed once and incubated for 2 hours m culture medium without additions before exposure to light. The cells were incubated at 37°C for 2 days, subcultured and further incubated for an additional 5 days before analysis of GFP expression by flow cytometry. HCT-116 cells were incubated with 20 μg/ml AlPcS 2d for 18 hours, washed and transfected with plasmid-pLys complexes for 6 hours before light exposure m plasmid- free medium. After 40 hours incubation at 37°C the GFP expression was studied by microscopy. Flow cytometry analysis The cells were trypsmised, centrifuged, resuspended m 400 μl of culture medium and filtered through a 50 μm mesh nylon filter. The cells were then analysed m a FACStar plus flow cytometer (Becton Dickinson) . Green Fluorescent Protein (GFP) was measured through a 510-530 nm filter after excitation with an argon laser (200 mW) tuned on 488 nm. AlPcS ^ was measured through a 650 nm longpass filter after excitation with a krypton laser (50 mW) tuned on 351-356 nm. Cell doublets were discriminated from single cells by gating on the pulse width of the GFP fluorescence signal. The data were analysed with PC Lysys II software (Becton Dickinson) . Preparation of Fluorescem-Pept de and Treatment of Cells The fluorescem-labelled Val -p2l -peptide (residues 5- 21 were synthesised and provided by Alan Cutnbertson, Nycomed Amersham) . BL2-G-E6 cells were incubated with 30 μg/ml of the fluorescein-labelled p21 ras -derived peptide for 18 hours followed by 20 μg/ml AlPcS 2a for 18 hours and 1 hour in drug-free medium before exposure to red light. Example 1 Photochemical intemalisation (PCI) can be used to enable peptides to enter the cytosol of cells To evaluate PCI for cytosolic delivery of cancer- specific peptides, a fluorescein-labelled p21 ras peptide encompassing residues 5-21 and containing a Val 12 mutation (G12V) was used (Gjertsen, M.K., et al . , Int. J. Cancer, 72: 784-790, 1997). In BL2-6-E6 mouse fibroblasts, the ras peptide colocalised well with AlPcS_-, indicating endocytic uptake of the peptide (Fig. 2) . After a 4-min exposure to light, the fluorescein- labelled ras peptide and AlPcS_, were found to be located diffusely in the cytoplasm. Similar effects were not observed in cells exposed to the fluorescein-labelled ras peptide and light only (data not shown) . Example 2 Use of PCI to induce antigen presentation and CD8' T lymphocyte mediated cell killing FM3 melanoma cells (2xl0 5 /well in 6 well plates) , grown m RPMI 1640 medium with 10% foetal calf serum (FCS) , not expressing MART-1 peptide were treated with 10 μg/ml of the photosensitising agent AlPcS 2d for 18 hours. The cells were then released from the substratum with EDTA (0.1 M) m Dulbecco's phosphate-buffered saline (PBS) and kept in solution during loading of the cells with 31 Cr (60 μCi/ml Na,Cr0 4 ) for 1 hour m 100% FCS followed by 5 hours incubation with 5 μg/ml MART-1 peptide m RPMI 1640 in 10% FCS, while the cells were still kept in solution. The sequence of the MART-1 peptide was: TAEEAAGIGILTVILG. The cells were then washed twice in RPMI 1640 medium containing 10% FCS and seeded out in 96-well plates (2000/well m 100 μl medium (RPMI 1640/10% FCS) . The cells were then exposed to light for the times as indicated m Figure 3 ( (Philips TL 20W/09) filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35 mW/cιτr (Rodal et al . , 1998, J. Photochem. Photobiol . B: Bioi . 45: 150- 9) ) . 18 hours after light exposure the medium was removed and medium containing MART-1/HLA-A2 specific cytotoxic T lymphocytes (CTLs - 40,000/well added m 100 μl) were added. After 4 hours of incubation the medium was separated from FM3 cells and the Cr released to the medium (as an indicator of lysed cells) was counted as well as the spontaneous and maximum release as previously described (Fossum et al . , 1995, Cancer Immunol. Immunother. 40: 165-172) . The percentage specific chromium release was calculated by the formula: (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100. It can be seen from tne results shown in Figure 3 that FM3 cells after PCI of a MART-1 peptide as outlined above show light dependent susceptibility to CD8 1 T lymphocyte cytotoxicity . Example 3 PCI induces the release of a large fraction of the endocytosed molecule This was shown by PCI induced intemalisation/ endocytosis of Horseradish Peroxidase (HRP) . By using HRP, it is demonstrated (see Figure 4) that PCI induces the release of a large fraction (>60%) of endocytosed HRP into the cytosol. In this experiment NHIK 3025 cells (carcinoma cells m situ from human cervix) were treated with the photosensitismg agent TPPS ^ (3.2 μg/ml) and 1 mg/ml HRP for 18 hours. The medium was then replaced with drug free medium before exposure to the light doses as indicated m Figure 4. HRP activity was measured according to the procedure described in Stemman et al . , J. Cell Biol., 68: 665-687, 1976. Cytosol was separated from cytosol-free cell corpses by electropermeabilisation and a density centπfugation technique (Berg et al . , Int. J. Cancer 59: 814-822, 1994) . Example 4 PCI can be used to enhance the delivery of functional genes To demonstrate this, THX cells were transfected with a pLys-complex of a plasmid (pEGFP-Nl) coding for green fluorescent protein (GFP^ . The expression of GFP was analysed by flow cytometry (Fig. 5, a and b) and fluorescence microscopy (data not shown) . As can be seen from Fig. 5a, treatment with AlPcS 2a and light led to a strong increase in the percentage of the cells expressing GFP. The fraction of the cells that was positive for this reporter molecule increased from 1% at no light treatment to 50% after a 5-min light exposure. GFP expression was not enhanced by light in cells treated with pEGFP-pLys in the absence of a photosensitiser. A complex of an irrelevant plasmid (encoding heme oxygenase) and pLys did not induce green fluorescence when combined with AlPcS 2a and light (data not shown) . Consequently, in a light-directed manner, PCI can substantially increase the efficiency of transfection of a functional gene to THX cells. Similar results were obtained using TPPS 2a as a photosensitiser and BHK-21 and HCT-116 as target cells (data not shown) . The essentially non-lysosomally located sensitiser 3- THPP induced only a minor increase in GFP expression (Fig. 5b) . PCI of pEGFP-Nl not complexed with pLys did not induce the expression of GFP (data not shown) .

Claims: 1. A method of expressing an antigenic molecule or a part thereof on the surface of a cell, said method comprising introducing a molecule into the cell cytosol by photochemical intemalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. 2. A method as claimed m claim 1, said method comprising : contacting said cell with said antigenic molecule or a part thereof and with a photosensitizing agent, wherein said molecule and said agent are each taken up into an mtracellular membrane-restricted compartment of said cell; and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, such that the membrane of said mtracellular compartment is disrupted, releasing said molecule into the cytosol of the cell, without killing the cell, wherein, said released antigenic molecule, or a part thereof, is subsequently presented on the surface of said cell . 3. The method of claim 1 or claim 2 wherein the antigenic molecule is a molecule capable of stimulating an immune response 4. The method of claim 3 wherein the antigenic molecule is a vaccine antigen or vaccine component 5. The method of any of the preceding claims wherein the antigenic molecule is a peptide 6. The method of any of the preceding claims wherein the cell is an antigen presenting cell selected from the group comprising lymphocytes, dendritic cells, macrophages and cancer cells. 7. The method of any of the preceding claims wherein the photosensitizing agent is selected from the group comprising porphyrins, phthalocyanines, purpuπns , chlor s, benzoporphyr s naphthalocyan es, catiomc dyes, tetracycl es and lysomotropic weak bases or derivatives thereof. 8. The method of claim 7 wherein the photosensitizing agent is TPPS„, TPPS 2a or AlPcS, a . 9. The method of any of the preceding claims wherein the antigenic molecule and/or photosensitizing agent is bound to one or more targeting agents or carrier molecules . 10. The method of any of the preceding claims wherein said method is carried out m vi tro or m vivo . 11. The method of any of the preceding claims wherein the antigenic presentation results the stimulation of an immune response . 12. A method of vaccination comprising the method as defined m any one of the preceding claims. 13. A composition for use expressing an antigenic molecule or a part thereof on the surface of a cell, said composition comprising an antigenic molecule as defined m any one of claims 1 to 5 or claim 9 and a photosensitizing agent as defined m any one of claims 2 or 7 to 9. 14. A cell expressing an antigenic molecule, or a part thereof, on its surface, oi a population thereof, which cell is obtainable by a method as defined m any one of claims 1 to 12. 15. A composition as defined claim 13 or a cell population as defined m claim 14 for use m therapy. 16. Use of an antigenic molecule and a photosensitizing agent as defined m the preceding claims the preparation of a medicament for use expressing said antigenic molecule or a part thereof on the surface of a cell to stimulate an immune response or for stimulating CTLs. 17. Use of a cell population as defined m claim 14 for the preparation of a medicament for stimulating an immune response or for stimulating CTLs. 18. Use as claimed m claim 16 or claim 17 wherein said medicament is used vaccination. 19. Use as claimed m any one of claims 16 to 18 wherein said medicament is used m the treatment of viral diseases, cancer or multiple sclerosis. 20. A product comprising an antigenic molecule as defined m any one of claims 1 to 5 or claim 9 and a photosensitizing agent as defined m any one of claims 2 or 7 to 9 as a combined preparation for simultaneous, separate or sequential use m expressing said antigenic molecule or a part thereof on the surface of a cell 21. A kit for use m expressing an antigenic molecule or a part thereof on the surface of a cell, said kit comprising a first container containing said antigenic molecule as defined any one of claims 1 to 5 or claim 9 ; and a second container containing a photosensitizing agent as defined in any one of claims 2 or 7 to 9.

Inventors: BERG KRISTIAN, HOGSET ANDERS, PRASMICKAITE LINA, TJELLE TORUNN E, BERG, KRISTIAN, HOGSET, ANDERS, PRASMICKAITE, LINA, TJELLE, TORUNN, E.
Applicants: BERG KRISTIAN, HOGSET ANDERS, JONES ELIZABETH LOUISE, PHOTOCURE ASA, PRASMICKAITE LINA, TJELLE TORUNN E, BERG, KRISTIAN, HOGSET, ANDERS, JONES, ELIZABETH, LOUISE, PRASMICKAITE, LINA, TJELLE, TORUNN, E.
Application year: 2000
Main classification: A61K39
IPC codes: A61K35, A61K39, A61K47, A61P25, A61P31, A61P35, A61P37, C12N5